Lupin pulls over 9,000 bottles of anti-infective Suprax from U.S.

MUMBAI Tue Apr 15, 2014 2:20pm IST

Various medicine pills in their original packaging are seen in Ljubljana February 14, 2012.   REUTERS/Srdjan Zivulovic/Files

Various medicine pills in their original packaging are seen in Ljubljana February 14, 2012.

Credit: Reuters/Srdjan Zivulovic/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Lupin Ltd is recalling 9,210 bottles of infection-preventing drug Suprax which failed a purity test in the United States, the U.S. Food and Drug Administration said.

The Suprax recall is the second for India's fourth-largest drugmaker by sales, after pulling nearly 65,000 bottles from the U.S. in January last year because of discoloration.

Recalls are not uncommon among drugmakers. This year alone, recalls have been conducted by all of Lupin's bigger local rivals - Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd and Dr. Reddy's Laboratories Ltd.

The latest recalled bottles of Suprax, used to prevent or treat bacteria-related infection, "did not meet specification in total impurities", the FDA said on its website on Monday. (r.reuters.com/myk58v)

The FDA classified the incident as a Class III recall, meaning use of or exposure to the drug is unlikely to cause any adverse health consequences.

A Lupin spokesperson on Tuesday confirmed the recall, which began in January, and said the company expects "no business consequence".

The recent recalls come amid increased FDA scrutiny of medicines produced in India, which supplies about 40 percent of generic and over-the-counter drugs sold in the U.S.

Indian drugmakers are heavily reliant on the U.S. where Lupin, for instance, derives around 40 percent of sales.

In September, Lupin also recalled over 53,000 bottles of hypertension drug quinapril from the U.S.

(Reporting by Zeba Siddiqui; Editing by Christopher Cushing)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Market Eye

REUTERS SHOWCASE

Bullish on Equities

Bullish on Equities

Bullish on Indian equities, but gains seen 'less sharp'- Goldman Sachs  Full Article 

Streamlining Operations

Jet Streamlines

Jet Airways chairman says looking to restructure debts, talking to bankers  Full Article 

Political Economy

Political Economy

Analysis - Watch what markets don't do as world politics turns nasty   Full Article 

Photo

Honda's India Thrust

Honda's India unit to account for 25 pct of Asia Pacific sales by March 2017 - exec   Full Article 

Short of Expectations

Short of Expectations

Apple revenue lags Street's view despite strong China growth  Full Article 

Mircosoft Results

Microsoft Results

Microsoft revenue rises, profit falls as Nokia absorbed  Full Article 

Relief For Sahara

Relief For Sahara

Supreme Court could allow Sahara boss to conduct asset sale talks, company says.  Full Article 

Photo

Food Scandal

Five held in China food scandal probe, including head of Shanghai Husi Food   Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage